Pages

▼

Saturday, 4 November 2017

Clinical Trials for Low KPS recurrent GBM patients

Hi all,

Is anyone aware of any Clinical trials taking place on the West Coast (USA) that consider low KPS recurrent GBM patients?

I've had my eye out for any reasonably non toxic options, but almost all trials have an entering criteria of >60-70kps score even for recurrent patients. My Father is closer to a 50.

I understand why 60/70 kps is standard, I'm just curious if others have heard of non toxic options for patients who cannot fully care for themselves.

We currently take various supplements and THC/CBD oil based on research from this forum, but are always open to more ideas.

My Dads original profile here, although he has since had a recurrence and is no longer taking TMZ:
http://btcocktails.blogspot.com/2017/02/tom-wangerin-cocktail-profile-and.html

Thank you to all

Ari
at

3 comments:

  1. Stephen W4 November 2017 at 16:43

    Hi Ari,
    Do you have a statement saying what his physician-assessed KPS or ECOG performance score currently is?

    Of all the trials on my radar, there are only a small handful of possibilities as far as clinical trials for people with low performance score.

    1. Expanded access protocol for VAL-083, though this wouldn't be considered non-toxic. https://clinicaltrials.gov/ct2/show/NCT03138629

    2. A couple of checkpoint inhibitor trials for advanced solid tumors don't list any performance status requirements (although these requirements may exist and didn't make it to the clinicaltrials.gov listing)

    https://www.clinicaltrials.gov/ct2/show/NCT02671435 (durvalumab [anti PD-L1] and monalizumab [anti NKG2A])

    https://clinicaltrials.gov/ct2/show/NCT02335918 (nivolumab + varlilumab)

    ReplyDelete
    Replies
    1. Stephen W4 November 2017 at 16:46

      Given the MGMT-methylated status of his tumor, there is a possibility the recurrence is hypermutated and would respond to one of the immune checkpoint inhibitors.

      Delete
    2. Stephen W4 November 2017 at 16:54

      Also, I'm curious about the complete results of the original FoundationOne testing. If there happened to be MDM2 amplification (which is fairly rare), that would be a strike against going the checkpoint inhibitor route. I recall you asked about abemaciclib at one time - this was just FDA approved for breast cancer about a month ago.

      Delete